SPRINT — Sprint Bioscience AB Share News
0.000.00%
Last trade - 00:00- SEK469.54m
- SEK361.22m
- SEK167.17m
Day One Biopharma rises on research, licensing deal with Sprint Bioscience
Brief: Sprint Bioscience Regains Rights To Nash Program
Brief: Sprint Bioscience Q1 Operating Loss SEK 12.3 Mln
Brief: Sprint Bioscience Q4 Operating Loss SEK 14.7 Million
Brief: Sprint Bioscience Reports Positive Results In Completed Nash Study
Brief: Sprint Bioscience Appoints Mathias Skalmstad As Acting CEO
Brief: Sprint Bioscience's Partner Hibercell Ends Cooperation On Petra01 Program
Brief: Sprint Bioscience CEO Erik Kinnman Resigns
Brief: Sprint Bioscience Gets Positive Partial Results In Ongoing Preclinical Study
Brief: Sprint Bioscience Q3 Operating Loss Narrows To SEK 12.5 Mln
Brief: Sprint Bioscience Resolves On Rights Issue Of Units Of About SEK 29.9 Mln
Brief: Sprint Bioscience Q2 Oper Loss Widens To SEK 18.2 Mln
Brief: Sprint Bioscience Expands Collaboration With Julian Walfridsson
Brief: Sprint Bioscience Q4 Operating Loss Widens To SEK 15.1 Mln
Brief: Sprint Bioscience Q3 Operating Result Swings To Profit SEK 17.3 Million
Brief: Sprint Bioscience AB Gets Financing From The Swedish Foundation For Strategic Research
Brief: Sprint Bioscience Q2 Operating Loss Widens To SEK 14.7 Million
Brief: Sprint Bioscience Says Licensed Cancer Drug Program VPS34 To Deciphera Pharmaceuticals
Brief: Sprint Bioscience Takes Up Convertible Loan, To Carry Out Rights Issue